TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.47 USD | -3.16% |
|
-2.25% | -21.14% |
| 18/04 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| 18/04 | Sector Update: Health Care | MT |
| Sales 2024 * | 268M 22.31B | Sales 2025 * | 416M 34.72B | Capitalization | 1.95B 163B |
|---|---|---|---|---|---|
| Net income 2024 * | -14M -1.17B | Net income 2025 * | 83M 6.92B | EV / Sales 2024 * | 7.1 x |
| Net cash position 2024 * | 51.91M 4.33B | Net cash position 2025 * | 116M 9.71B | EV / Sales 2025 * | 4.41 x |
| P/E ratio 2024 * |
-127
x | P/E ratio 2025 * |
25.9
x | Employees | 264 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on TG Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -3.16% | ||
| 1 week | -2.25% | ||
| Current month | -11.44% | ||
| 1 month | -12.76% | ||
| 3 months | -14.75% | ||
| 6 months | +87.08% | ||
| Current year | -21.14% |
1 week
13.29
14.57
1 month
13.2615.60
Current year
12.8422.67
1 year
6.4635.67
3 years
3.4845.50
5 years
3.4856.74
10 years
3.3256.74
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 18/93/18 |
Sean Power
DFI | Director of Finance/CFO | 42 | 29/11/29 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 18/93/18 |
Laurence Charney
BRD | Director/Board Member | 76 | 01/12/01 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 15/14/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 13.47 | -3.16% | 2,840,667 |
| 25/24/25 | 13.91 | -0.50% | 3,859,911 |
| 24/24/24 | 13.98 | -1.89% | 2,725,253 |
| 23/24/23 | 14.25 | +1.06% | 3,222,795 |
| 22/24/22 | 14.1 | +2.32% | 2,273,680 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.47
USD
Average target price
29.75
USD
Spread / Average Target
+120.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.14% | 1.95B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TGTX Stock
